Antisoma Initiates Phase II Kidney Cancer Study
Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma.
The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days for up to two cycles.
Efficacy measures in the trial include response rate, time to progression and progression-free survival. Final results are expected in 2010.
Glyn Edwards, Antisoma’s CEO, said: “Evidence to date suggests that AS1411 has broad potential against blood cancers and solid tumors. With Phase II trials now ongoing in both acute myeloid leukemia and kidney cancer, we are testing AS1411 in diverse settings, and look forward to the roll-out of clinical data over the next two years.”